Halofantrine

Summary

Halofantrine (CHEMBL1107) is an approved small molecule (ATC P01BX01) targeting KCNH2; indicated across 1 condition including malaria.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: P01BX01
• Targets: 1 (KCNH2)
• Indications: 1 condition
• Chemistry: 500.4 Da · C26H30Cl2F3NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1107
Name	Halofantrine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	37393
ATC	P01BX01
Molecular formula	C26H30Cl2F3NO
Molecular weight	500.4
InChIKey	FOHHNHSLJDZUGQ-UHFFFAOYSA-N

SMILES: CCCCN(CCCC)CCC(C1=C2C=CC(=CC2=C3C=C(C=C(C3=C1)Cl)Cl)C(F)(F)F)O

IUPAC name: 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl]propan-1-ol

Also known as: DL-WR-171669, Halofantrina, Halofantrine, halofantrine, Halofantrin, HALOFANTRINE, HALOFANTRINE.HCL, Halofantrine hydrochlorideÊ, Halofantrine_HCL, Halofantrine hydrochlorideÂ

Parent form; salt/anhydrous children: CHEMBL1200901, CHEMBL1966423

Patent coverage: 2,223 distinct patent families (9,722 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 9,690 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
KCNH2	Kv11.1	Inhibition	7.4	0.3%	Q12809

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Voltage-gated L-type calcium channel, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 15 potent at pChembl ≥ 5 of 16 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	7.4	IC50	40	nM	CHEMBL_ACT_1449649
KCNH2	7.4	IC50	40	nM	CHEMBL_ACT_2395357
KCNH2	6.81	IC50	156	nM	CHEMBL_ACT_18062974
KCNH2	6.8	IC50	160	nM	CHEMBL_ACT_24959578
KCNH2	6.8	IC50	160	nM	CHEMBL_ACT_29118759
KCNH2	6.71	IC50	196	nM	CHEMBL_ACT_306562
KCNH2	6.71	IC50	195	nM	CHEMBL_ACT_5218932
KCNH2	6.7	IC50	199.5	nM	CHEMBL_ACT_1033547
KCNH2	6.7	IC50	199.5	nM	CHEMBL_ACT_1427122
KCNH2	6.7	IC50	199.5	nM	CHEMBL_ACT_1523672
KCNH2	6.7	IC50	199.5	nM	CHEMBL_ACT_2358303
KCNH2	6.7	IC50	199.5	nM	CHEMBL_ACT_2645520
KCNH2	6.21	AC50	620	nM	CHEMBL_ACT_25118602
CACNA1F	5.72	IC50	1900	nM	CHEMBL_ACT_15373330
KCNH2	5.12	Ki	7500	nM	CHEMBL_ACT_13860055

Target pathways

Aggregated over 1 target gene(s): KCNH2.

Top Reactome pathways

6 total, by targets touching each:

Pathway	Targets	Genes
Neuronal System	1	KCNH2
Potassium Channels	1	KCNH2
Voltage gated Potassium channels	1	KCNH2
Muscle contraction	1	KCNH2
Phase 3 - rapid repolarisation	1	KCNH2
Cardiac conduction	1	KCNH2

Dominant GO biological processes

GO term	Targets
regulation of heart rate by hormone	1
potassium ion transport	1
regulation of membrane potential	1
positive regulation of DNA-templated transcription	1
potassium ion homeostasis	1
cardiac muscle contraction	1
regulation of membrane repolarization	1
regulation of ventricular cardiac muscle cell membrane repolarization	1
cellular response to xenobiotic stimulus	1
potassium ion transmembrane transport	1
ventricular cardiac muscle cell action potential	1
membrane repolarization	1
membrane depolarization during action potential	1
membrane repolarization during action potential	1
membrane repolarization during cardiac muscle cell action potential	1

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
malaria	4	MONDO:0005136	EFO:0001068

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

617 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
AFATINIB	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
DIHYDROERGOTAMINE	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
GENTIAN VIOLET	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
MAVORIXAFOR	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
PIMAVANSERIN	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
PROPOXYPHENE	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
RELUGOLIX	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
RIOCIGUAT	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
VORAPAXAR	ChEMBL + PubChem	Phase 4 (approved)	KCNH2
ABEMACICLIB	ChEMBL	Phase 4 (approved)	KCNH2
ACENOCOUMAROL	ChEMBL	Phase 4 (approved)	KCNH2
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	KCNH2
ACLIDINIUM BROMIDE	ChEMBL	Phase 4 (approved)	KCNH2
ALBENDAZOLE	ChEMBL	Phase 4 (approved)	KCNH2
ALMOTRIPTAN	ChEMBL	Phase 4 (approved)	KCNH2
ALOSETRON	ChEMBL	Phase 4 (approved)	KCNH2
ALPIDEM	ChEMBL	Phase 4 (approved)	KCNH2
AMBENONIUM	ChEMBL	Phase 4 (approved)	KCNH2
AMCINONIDE	ChEMBL	Phase 4 (approved)	KCNH2
AMIODARONE	ChEMBL	Phase 4 (approved)	KCNH2
AMISULPRIDE	ChEMBL	Phase 4 (approved)	KCNH2
AMITRIPTYLINE	ChEMBL	Phase 4 (approved)	KCNH2
AMLODIPINE	ChEMBL	Phase 4 (approved)	KCNH2
AMODIAQUINE	ChEMBL	Phase 4 (approved)	KCNH2
AMOROLFINE	ChEMBL	Phase 4 (approved)	KCNH2
AMOXAPINE	ChEMBL	Phase 4 (approved)	KCNH2
AMSACRINE	ChEMBL	Phase 4 (approved)	KCNH2
ANISOTROPINE	ChEMBL	Phase 4 (approved)	KCNH2
ANTAZOLINE	ChEMBL	Phase 4 (approved)	KCNH2
APOMORPHINE	ChEMBL	Phase 4 (approved)	KCNH2
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	KCNH2
ASCIMINIB	ChEMBL	Phase 4 (approved)	KCNH2
ASENAPINE	ChEMBL	Phase 4 (approved)	KCNH2
ASTEMIZOLE	ChEMBL	Phase 4 (approved)	KCNH2
ATOMOXETINE	ChEMBL	Phase 4 (approved)	KCNH2
ATRACURIUM	ChEMBL	Phase 4 (approved)	KCNH2
AVATROMBOPAG	ChEMBL	Phase 4 (approved)	KCNH2
AZELASTINE	ChEMBL	Phase 4 (approved)	KCNH2
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	KCNH2
BEDAQUILINE	ChEMBL	Phase 4 (approved)	KCNH2
BENFLUOREX	ChEMBL	Phase 4 (approved)	KCNH2
BENOXINATE	ChEMBL	Phase 4 (approved)	KCNH2
BENPERIDOL	ChEMBL	Phase 4 (approved)	KCNH2
BENZPHETAMINE	ChEMBL	Phase 4 (approved)	KCNH2
BENZTROPINE	ChEMBL	Phase 4 (approved)	KCNH2
BENZYDAMINE	ChEMBL	Phase 4 (approved)	KCNH2
BEPRIDIL	ChEMBL	Phase 4 (approved)	KCNH2
BERBERINE	ChEMBL	Phase 4 (approved)	KCNH2
BETRIXABAN	ChEMBL	Phase 4 (approved)	KCNH2
BEXAROTENE	ChEMBL	Phase 4 (approved)	KCNH2
BIFONAZOLE	ChEMBL	Phase 4 (approved)	KCNH2
BIPERIDEN	ChEMBL	Phase 4 (approved)	KCNH2
BITHIONOL	ChEMBL	Phase 4 (approved)	KCNH2
BOSUTINIB	ChEMBL	Phase 4 (approved)	KCNH2
BROMHEXINE	ChEMBL	Phase 4 (approved)	KCNH2
BROMPERIDOL	ChEMBL	Phase 4 (approved)	KCNH2
BUCLIZINE	ChEMBL	Phase 4 (approved)	KCNH2
BUFLOMEDIL	ChEMBL	Phase 4 (approved)	KCNH2
BUPIVACAINE	ChEMBL	Phase 4 (approved)	KCNH2
BUPRENORPHINE	ChEMBL	Phase 4 (approved)	KCNH2